CST4, the full name of human cysteine protease inhibitor S (CST4), is a gastrointestinal tumor marker exclusively developed by our company and the first in the world.

Usually 5 working days.

Clinical trials conducted by Peking Union Medical College Hospital etc. show that the sensitivity of our test is 60.4%-64%, and the specificity is 82.7%-83.4%. The data is accurate and reliable and can be used for the screening of gastrointestinal tumors.

Symptoms of gastrointestinal discomfort;

People with chronic gastrointestinal diseases;

Middle-aged and elderly people in high-incidence areas of gastrointestinal cancer (over 40 years old);

Patients with gastrointestinal cancer after surgical treatment;

family members of patients with gastrointestinal cancer;

Patients with familial gastrointestinal adenomatosis.

Studies have found that with the growth, invasion and metastasis of gastrointestinal tumor cells, the expression of CST4 increases, and a higher concentration of CST4 protein can be detected in the serum of patients with gastrointestinal tumors, with high organ specificity and early detection rate. By detecting the expression of CST4, early screening, auxiliary diagnosis, curative effect evaluation and disease monitoring of gastrointestinal cancer can be completed.

Avoid eating high-fat, high-protein foods within 8 hours before the test;

Female customers should try to avoid blood during menstruation (if there are special circumstances, please inform customer service or indicate in the health questionnaire);

Fasting blood collection;

Use a coagulation-promoting blood collection tube (yellow cap with separating gel), and collect 5 ml of peripheral blood. After sampling, turn the blood collection tube upside down and shake it gently for 5 times to fully fuse the solution in the tube with the blood sample. About 30min, no more than 2h at the latest), centrifuge at 4000rpm for 5min, aspirate the serum, transfer it to a 2mL centrifuge tube, label the centrifuge tube and blood collection tube with customer information, and transport to the corresponding laboratory for testing.

If your test result is negative, it means that there is no obvious abnormality of gastrointestinal tumor protein markers in your test sample. We recommend that you maintain good living habits and undergo regular screening.

However, our test items cannot cover 100% of related tumors. If you have obvious gastrointestinal symptoms, we still recommend you to go to the hospital for related examinations.

Not necessarily an existing tumor. A positive result indicates that abnormal gastrointestinal tumor protein markers were detected in this sample, and there is a high risk of malignant gastrointestinal tumors in the body. As for whether there must be tumors, further examination is needed to confirm the diagnosis.

CST4 is a new tumor marker developed exclusively by us. It is a patented product with 20-year property rights protection. At present, there is no other similar product on the market.

Non-invasive and fast: only 5ml of venous blood is needed, no needle biopsy is required, and the result can be obtained within 5 working days.

Accurate and reliable: the sensitivity is 60.4%-64%, and the specificity is 82.7%-83.4%.

Authoritative certification: global exclusive invention patent, 20 years of intellectual property protection, national 863 class III IVD project for clinical transformation, NMPA class III medical device registration certificate and EU CE certification.

CE certification, patent certificate, medical device registration certificate, "863" subject book, written into the 2021 expert consensus

All major private physical examination institutions in the country are available for sale. You can also contact us for consultation through the official website of Jiangsu Microdiag or the WeChat public account of "Jiangsu Microdiag".

DR-70 is used for early screening and curative effect of 13 cancers including lung cancer, stomach cancer, breast cancer, colon cancer, rectal cancer, esophageal cancer, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, bladder cancer, head and neck cancer, and prostate cancer. Assessment and disease surveillance.

Usually 5 working days.

DR-70 detects the degradation products of fibrin/fibrinogen in human blood, and traces of tumors in vivo can be found by DR-70 detection. Our assay has a sensitivity of 65.2%-96.5% and a specificity of over 90%.

Healthy people with a family history of cancer;

Certain pathogenic microorganisms such as HBV, HPV, Helicobacter pylori carriers;

Immunocompromised or immunocompromised people;

Patients with chronic diseases such as diabetes, liver cirrhosis, gastric ulcer, intestinal polyps, obesity, etc.;

Those who have lost weight sharply in a short period of time; those who have fever, pain, and lumps on the body surface for unknown reasons;

White-collar workers with high work pressure, etc.;

Living habits need to be improved, such as smokers and people who stay up late.

The occurrence of tumor is always accompanied by abnormal fibrinolysis system and increase of serum DR-70 concentration. The trace of tumor can be found by DR-70 detection, so DR-70 detection can be used for early tumor screening.

Avoid eating high-fat, high-protein foods within 8 hours before the test;

Female customers should try to avoid blood during menstruation (if there are special circumstances, please inform customer service or indicate in the health questionnaire);

Fasting blood collection;

Use a coagulation-promoting blood collection tube (yellow cap with separating gel), and collect 5 ml of peripheral blood. After sampling, turn the blood collection tube upside down and shake it gently for 5 times to fully fuse the solution in the tube with the blood sample. About 30min, no more than 2h at the latest), centrifuge at 4000rpm for 5min, aspirate the serum, transfer it to a 2mL centrifuge tube, label the centrifuge tube and blood collection tube with customer information, and transport to the corresponding laboratory for testing.

If your test result is negative, it means that there is no obvious abnormality in the tumor protein marker DR-70 in your test sample. We recommend that you maintain good living habits and have regular physical examinations.

However, our test items cannot cover related tumors 100%. If you have obvious related symptoms, we still recommend you to go to the hospital for related examinations.

Not necessarily an existing tumor. A positive result indicates that abnormal tumor protein marker DR-70 was detected in this sample, and there is a high risk of malignant tumor in the body. As for whether there is a tumor, further examination is needed to confirm the diagnosis.

DR-70 is a new broad-spectrum tumor marker introduced exclusively by us, which is currently exclusive in China.

Non-invasive and fast: only 5ml of venous blood is needed, no needle biopsy is required, and the result can be obtained within 5 working days.

Accurate and reliable: more than 90% specificity, 65.2-96.5% sensitivity (varies according to different tumor types)

Authoritative guarantee: US FDA certification, effectiveness confirmed by top international research institutions

DR-70 is the first FDA-approved tumor marker since 1982. It has been certified and widely used and promoted in the United States, the European Union, Canada, South Korea, Japan and other countries. Class III medical device registration certificate, registration certificate number: National Machinery Note 20193400068

All major private physical examination institutions in the country are available for sale. You can also contact us for consultation through the official website of Jiangsu Microdiag or the WeChat public account of "Jiangsu Microdiag".

Septin9 gene methylation detection can be used for early screening, auxiliary diagnosis and disease monitoring of colorectal cancer.

Usually 5 working days.

The results of clinical trials conducted by 6 institutions including Peking University Cancer Hospital, Zhejiang Cancer Hospital, the First Affiliated Hospital of Zhejiang University School of Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Wuxi Fourth People's Hospital, and Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences show that , Septin9 gene methylation detection has a sensitivity of 76.45% and a specificity of 90.32%. The detection is accurate and reliable, safe and non-invasive, and can be used for early screening, auxiliary diagnosis and postoperative recurrence monitoring of colorectal cancer.

People over 40 years old in high-incidence areas;

People with intestinal symptoms or history of polyps;

People with a family history of bowel cancer;

Patients after bowel cancer surgery;

Septin9 gene methylation is one of the main reasons for colorectal cancer carcinogenesis. The methylation level of Septin9 gene key sites increases with the development of tissue carcinogenesis, which has excellent tumor and organ dual specificity. Septin9 gene methylation Detection can detect early-stage colorectal cancer for early intervention and treatment, which greatly improves survival.

S9 testing is not recommended for customers who are pregnant, have a history of organ transplantation, or have a history of blood transfusion within 6 months;
Avoid high-fat foods 8 hours before the test;
There is no need for an empty stomach, please fill in the "Health Test Form" carefully before the test.

Use EDTA-K2 anticoagulant blood collection tube (purple cap), collect 5ml of peripheral blood. After sampling, turn the blood collection tube upside down and shake gently for 5 times, centrifuge at 4000 rpm for 5 minutes, aspirate the plasma, and transfer it to a centrifuge tube. Both the centrifuge tube and the blood collection tube are attached After uploading the customer information, add ice and transport it to the corresponding inspection office for testing.

If your test result is negative, it means that there is no abnormal methylation of S9 in your test sample, and the risk of colorectal cancer is low. We recommend that you maintain good living habits and undergo regular screening.

However, our test items cannot cover 100% of related tumors. If you have obvious bowel-related symptoms, we still recommend you to go to the hospital for related examinations.

If the Septin9 gene methylation test result is positive, we recommend that you have a colonoscopy, and if confirmed, the clinician will provide the means of intervention and treatment.

Our company's S9 project can do: detect early cancer; sensitivity and specificity are better than existing colorectal cancer screening methods (fecal occult blood, conventional serum tumor markers, etc.); minimally invasive and fast; make up for the lack of colonoscopy Invasive pain and pitfalls of differences in detection rates of left and right colon cancer in fecal occult blood testing.

The Septin9 gene methylation blood test for screening colorectal cancer has been recognized internationally. The FDA approved the Septin9 gene methylation test for early screening of colorectal cancer. It is true S9 that has been approved by the State Food and Drug Administration. Class medical device registration certificate, registration certificate number: National Machinery Note 20183400103.

All major private physical examination institutions in the country are available for sale. You can also contact us for consultation through the official website of Jiangsu Microdiag or the WeChat public account of "Jiangsu Microdiag".

All major private physical examination institutions in the country are available for sale. You can also contact us for consultation through the official website of Jiangsu Microdiag or the WeChat public accounts of "Jiangsu Weizhen" and "Waizhen Great Health".

Usually 10 working days.

It is advisable to have a light diet 3 days before blood collection, avoid meat and greasy food 1 day before blood collection; maintain a normal daily routine and avoid overwork and staying up late;
Morning blood is collected on an empty stomach before 10:00 in the morning, and the fasting time is required to be more than 12 hours (fasting after 20:00 the day before);
Do not do strenuous exercise before blood collection, relax your mind, and avoid abnormal emotional fluctuations;
Female customers should try to avoid blood during menstruation and pregnancy (if there are special circumstances, please inform customer service or indicate in the health questionnaire);
Avoid taking blood on the day of taking medicine (including traditional Chinese medicine, western medicine) or health care products. Avoid blood samples from people who have received an allogeneic blood transfusion within one year or a bone marrow transplant within two years.

Clients with lung nodules detected on chest X-ray or CT.

Because the detection method of lung clearing products is to use next-generation deep sequencing technology (NGS) and tumor-derived exosome targeted capture and miRNA detection technology (Ultra-miRs PCR) at the same time. Capture the trace amount of circulating tumor DNA fragments (ctDNA) as low as 0.1% and trace exosomes released by cancerous cells in peripheral blood for detection, and in-depth detection (10000x) of 50 genes and exosome markers highly related to lung cancer. Reliably, safely, non-invasively, and conveniently provides information about the release of pulmonary nodule lesions into peripheral blood, assisting and excellent clinical comprehensive diagnosis. With a relatively high technical threshold, the cost will be relatively high; because it is a testing technology independently developed by Microdiag, the price of this product will be more competitive compared to other testing products of the same type in the industry.

Feijingqing is a combined detection of ctDNA + exosomes for auxiliary risk assessment of benign and malignant pulmonary nodules.

ctDNA (circulating tumor DNA) is tumor cell DNA that carries tumor-specific information and is a marker of tumors scattered in the blood. Through ctDNA detection, tumor traces in the blood can be detected.

Usually 10 working days.

Although the current tumor treatment technology and methods have made great progress, the mortality rate of most cancers is still high. Clinical studies have found that 90% of patients with tumors detected early can be cured. However, due to the limitations of conventional detection techniques, only a small number of people are diagnosed with cancer at an early stage. In my country, early (stage I) cancer patients account for about 5% to 10% of the total number of patients, and 70% of the patients are late detection and lost The best time for treatment, the 5-year survival rate is only 10%-30%. Therefore, early detection is the key to cancer treatment.

18 types of tumors can be screened at one time, divided into 18 males and 18 females.

Men: Testicular cancer, prostate cancer, penile cancer, throat cancer, lung cancer, liver cancer, pancreatic cancer, stomach cancer, esophagus cancer, kidney cancer, thyroid cancer, colorectal cancer, bladder cancer, nasopharyngeal cancer, oral cancer, gallbladder cancer, brain cancer Glioma, osteosarcoma

Women: ovarian cancer, endometrial cancer, breast cancer, cervical cancer, lung cancer, liver cancer, pancreatic cancer, stomach cancer, esophagus cancer, kidney cancer, thyroid cancer, colorectal cancer, bladder cancer, nasopharyngeal cancer, oral cancer, gallbladder cancer , glioma, osteosarcoma

People with chronic inflammation or precancerous lesions, such as hepatitis, chronic ulcer disease, diabetes, gastrointestinal polyps, cervical erosion, breast cystic hyperplasia, thyroid nodules, etc.;

People with bad habits, such as long-term smokers, alcoholics, people who hold back urine, people who often stay up late, people who eat meat, people with vitamin deficiencies, people who often drink hot boiled water, people with low cholesterol and other factors;

Immediate family members of cancer patients;

Allergic;

engage in high-risk occupations;

Over 45 years old, living in a big city for a long time, occupation with high work pressure;

Prolonged exposure to hazardous chemicals or radiation for occupational and environmental reasons;

Long-term smokers, drinkers, and excessive intake of high-fat foods lead to obesity.

Avoid eating high-fat, high-protein foods within 8 hours before the test;

Female customers should try to avoid blood during menstruation (if there are special circumstances, please inform customer service or indicate in the health questionnaire);

You can eat properly, please fill in the "Health Test Form" carefully;

Use a special non-invasive blood collection tube (brown rubber head cover) to collect 10ml of peripheral blood. After sampling, turn the blood collection tube upside down and shake it gently for 10 times to fully integrate the solution in the tube with the blood sample. The blood collection tube is pasted with customer information and transported to Suzhou General Hospital at room temperature. Tested by Remed Laboratory.

The absence of mutations in the test result does not necessarily mean that there is no tumor. Our test items are not yet able to cover 100% of related tumors, and it is estimated that about 10%-20% may be missed. The genes we detect are all organized based on data from clinical research results, and the accuracy of this technology will become more and more precise as relevant gene mining is supplemented.

A mutation in the test result is not necessarily a pre-existing tumor. Our test results have gene mutations, indicating that cancer (changed) cells already exist in the body. As for whether a tumor has formed, further examination is required to determine.

For tumor mutation carriers detected by ultra-early screening, we recommend going to the hospital for further examination by imaging methods such as PET-CT to determine whether a tumor has formed.

If it has already formed, it needs to be clinically treated by means of hospital surgery, radiotherapy and chemotherapy. If no tumor is found, it indicates that the tumor mutation carrier is in a state of precancerous lesions, and certain preventive intervention measures need to be taken to make the mutant gene return to normal and prevent the further development of cancer.

If the test results have mutations, and the results of in-depth examinations such as hospital imaging, tumor markers, and organ function are "no abnormality", we preliminarily judge that they are precancerous and have not yet reached the stage of malignant tumors visible on imaging. This stage is still in the "latency period" (precancerous stage) of cancer. According to individual differences, improve bad living habits, stay away from carcinogens, and use appropriate interventions.

Different. For susceptibility testing, the samples tested are normal cells in any part of the human body, such as oral mucosa. The test result only reflects the possibility that the patient is more likely to get cancer than the average person because of heredity. It has nothing to do with the current state of the body. It is only a susceptibility risk. A positive test does not indicate that the subject is cancer. precancerous lesions or cancer.

Ultra-early screening detects mutated genes specific to the tumor. The sample tested is DNA specific to tumor cells. The person whose mutation is detected is called a tumor gene mutation carrier, indicating that the person is in precancerous lesions, or is already a tumor patient. In people with precancerous lesions, we can make it possible to reverse it by means of intervention. Patients diagnosed with cancer by the hospital are recommended to go to clinical treatment.

All major private physical examination institutions in the country are available for sale. You can also contact us for consultation through the official website of Jiangsu Weizhen or the WeChat public account of "Jiangsu Microdiag".